Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc. News
Dec 4, 2024 - newsfilecorp.com
BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory Board
Jul 15, 2024 - investorplace.com
3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off
Jun 24, 2024 - globenewswire.com
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
May 20, 2024 - globenewswire.com
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
eFFECTOR Therapeutics, Inc. Quantitative Score
About eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
eFFECTOR Therapeutics, Inc. Earnings & Revenue
eFFECTOR Therapeutics, Inc. Financials
Table Compare
Compare EFTR metrics with: | |||
|---|---|---|---|
Earnings & Growth | EFTR | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | EFTR | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | EFTR | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | EFTR | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
eFFECTOR Therapeutics, Inc. Income
eFFECTOR Therapeutics, Inc. Balance Sheet
eFFECTOR Therapeutics, Inc. Cash Flow
eFFECTOR Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
eFFECTOR Therapeutics, Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
eFFECTOR Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Mr. Craig R. Jalbert CIRA | Chief Executive Officer, President, Treasurer &Secretary, and Director |
| Dr. Davide Ruggero Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board |
| Dr. Kevan M. Shokat Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Craig R. Jalbert CIRA | Chief Executive Officer, President, Treasurer &Secretary, and Director | Male | 1962 | -- |
| Dr. Davide Ruggero Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board | -- | ||
| Dr. Kevan M. Shokat Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board | -- |
eFFECTOR Therapeutics, Inc. Insider Trades
| Date | 13 Jun |
| Name | Loewy Caroline M |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 800 |
| Date | 13 Jun |
| Name | Klencke Barbara |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 800 |
| Date | 13 Jun |
| Name | Ehrlich Christopher B |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 800 |
| Date | 13 Jun |
| Name | Harrington-Smith Kristen |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 800 |
| Date | 13 Jun |
| Name | Gallagher Brian M. Jr. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 800 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 13 Jun | Loewy Caroline M | Director | Acquired | A-Award | 800 |
| 13 Jun | Klencke Barbara | Director | Acquired | A-Award | 800 |
| 13 Jun | Ehrlich Christopher B | Director | Acquired | A-Award | 800 |
| 13 Jun | Harrington-Smith Kristen | Director | Acquired | A-Award | 800 |
| 13 Jun | Gallagher Brian M. Jr. | Director | Acquired | A-Award | 800 |